Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.69 |
| ▸ | BCR | P11274 | 14/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.65 |
| ▸ | KIT | P10721 | 2/20 | 0.65 |
| ▸ | EGFR | P00533 | 2/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.65 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719554 | 0.89 | ABL1 (0.73) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL4825993 | 0.88 | ABL1 (0.70) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL4087640 | 0.88 | ABL1 (0.82) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL714756 | 0.87 | ABL1 (0.76) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL3794413 | 0.87 | ABL1 (0.76) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL715666 | 0.87 | ABL1 (0.76) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL716168 | 0.87 | ABL1 (0.75) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL1096984 | 0.87 | ABL1 (0.75) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL716396 | 0.86 | ABL1 (0.75) | ABL1BCRPDGFRBHDAC3KDR | |
| SCHEMBL715902 | 0.86 | ABL1 (0.75) | ABL1BCRPDGFRBHDAC3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | claimed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | claimed |
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8835435-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | AB SCIENCE (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8450302-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120053186-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2012-03-01 | — | — | US | disclosed |
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | AB SCIENCE | 2008-10-16 | — | — | US | disclosed |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | AB SCIENCE | 2008-10-16 | — | — | US | disclosed |
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | disclosed |
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | disclosed |
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | AB SCIENCE | 2007-08-16 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | AB SCIENCE | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053186-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | KIT, CHUK, MAP3K2 | ABL1 40/4885BCR 226/4885PDGFRB 38/4885 |
| US-20110201620-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | KIT, ABL1, MUSK | ABL1 2/4885BCR 746/4885PDGFRB 89/4885 |
| US-20070032521-A1 | Use of c-kit inhibitors for treating type II diabetes | KIT, CPA3, CMA1 | ABL1 233/4885BCR 3609/4885PDGFRB 213/4885 |
| US-20070191267-A1 | Use of tyrosine kinase inhibitors for treating cerebral ischemia | KIT, MAST3, CPA3 | ABL1 14/4885BCR 2136/4885PDGFRB 82/4885 |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | KIT, CHUK, CKS1B | ABL1 22/4885BCR 167/4885PDGFRB 41/4885 |
| US-20080255141-A1 | Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders | KIT, MAP3K1, MAP3K6 | ABL1 176/4885BCR 389/4885PDGFRB 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.